Differential recovery of polymorphonuclear neutrophils, B and T cell subpopulations in the thymus, bone marrow, spleen and blood of mice following split-dose polychemotherapy

Cancer Immunol Immunother. 1994 Jul;39(1):59-67. doi: 10.1007/BF01517182.


In these studies, we examined the effect of a maximum-tolerated, split-dose chemotherapy protocol of cyclophosphamide, cisplatin, and 1,3-bis(2-chloroethyl)-1-nitrosourea carmustine on neutrophil and lymphocyte, subpopulations in the peripheral blood (PBL), thymus, bone marrow and spleen. It was found that this protocol of polychemotherapy, modeled after the induction protocol used with autologous bone marrow transplantation for breast cancer, suppressed both B and T cell populations and T cell function at times when the absolute neutrophil count had returned to normal or supernormal numbers. In the peripheral blood, 7 days following initiation of chemotherapy, there was a twofold increase in the percentage of granulocytes as compared to the level in control animals on the basis of a differential count. The polymorphonuclear neutrophil (PMN) frequency in the bone marrow was increased on day 14 and statistically identical to that in control mice on all other days analyzed. In contrast to the bone marrow cells and PBL on day 7, the frequency of PMN in the spleen and thymus was depressed. B cells (B220+) were depressed in the pBL, spleen and bone marrow and took 18-32 days to return to their normal frequency, while the frequency of B cells in the thymus was increased owing to a loss of immature T cells. The percentage of CD3+ cells in the thymus, spleen and bone marrow was significantly increased and required 10-18 days to return to normal levels, while the absolute number of CD3+ cells in the blood varied around the normal value. The ratio of CD4+ to CD8+ cells in all the organs studied varied only slightly owing to a similar reconstitution of CD4+ and CD8+ cells. In contrast to the phenotypic recovery of the CD3+, CD4+, and CD8+ cells, the ability of the splenic lymphocytes to respond to concanavalin-A was depressed and remained depressed, despite the phenotypic reconstitution of the T cell subsets, on the basis of both percentage and absolute cell number. These results show a selective T and B cell depression following multi-drug, split-dose chemotherapy in tissue and blood leukocyte populations and a chronic depression in T cell function.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / toxicity*
  • B-Lymphocyte Subsets / drug effects*
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / physiology
  • Bone Marrow / drug effects*
  • Bone Marrow Cells*
  • CD4-CD8 Ratio / drug effects
  • Carmustine / administration & dosage
  • Cell Separation
  • Cisplatin / administration & dosage
  • Concanavalin A / pharmacology
  • Cyclophosphamide / administration & dosage
  • Female
  • Flow Cytometry
  • Mice
  • Mice, Inbred BALB C
  • Neutrophils / drug effects*
  • Neutrophils / physiology
  • Spleen / cytology*
  • Spleen / drug effects*
  • Stimulation, Chemical
  • T-Lymphocyte Subsets / drug effects*
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / physiology
  • Thymus Gland / cytology*
  • Thymus Gland / drug effects*


  • Concanavalin A
  • Cyclophosphamide
  • Cisplatin
  • Carmustine